Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Timothy N. Hoang, Maria Pino, Arun K. Boddapati, Elise G. Viox, Carly E. Starke, Amit A. Upadhyay, Sanjeev Gumber, Michael Nekorchuk, Kathleen Busman-Sahay, Zachary Strongin, Justin L. Harper, Gregory K. Tharp, Kathryn L. Pellegrini, Shannon Kirejczyk, Keivan Zandi, Sijia Tao, Tristan R. Horton, Elizabeth N. Beagle, Ernestine A. Mahar, Michelle Y.H. LeeJoyce Cohen, Sherrie M. Jean, Jennifer S. Wood, Fawn Connor-Stroud, Rachelle L. Stammen, Olivia M. Delmas, Shelly Wang, Kimberly A. Cooney, Michael N. Sayegh, Lanfang Wang, Peter D. Filev, Daniela Weiskopf, Guido Silvestri, Jesse Waggoner, Anne Piantadosi, Sudhir P. Kasturi, Hilmi Al-Shakhshir, Susan P. Ribeiro, Rafick P. Sekaly, Rebecca D. Levit, Jacob D. Estes, Thomas H. Vanderford, Raymond F. Schinazi, Steven E. Bosinger, Mirko Paiardini

Research output: Contribution to journalArticlepeer-review

135 Scopus citations

Abstract

Using a rhesus macaque infection model, it is shown that baricitinib treatment started early after infection effectively resolves inflammatory signatures in airway macrophages, with decreased lung pathology and neutrophil infiltration.

Original languageEnglish (US)
Pages (from-to)460-475.e21
JournalCell
Volume184
Issue number2
DOIs
StatePublished - Jan 21 2021

Keywords

  • COVID-19
  • SARS-CoV-2
  • baricitinib
  • immune activation
  • immunology
  • inflammation
  • nonhuman primate
  • pathogenesis

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques'. Together they form a unique fingerprint.

Cite this